The measles vaccine M-VAC™ (Serum Institute of India) includes tricine, amino acids (alanine, arginine, histidine), and stabilizers Afatinib clinical trial (lactalbumin hydrolysate, hydrolyzed gelatin) [26]. Measles virus encoding enhanced green fluorescent protein [27] (MVeGFP) was grown by infecting a 50% confluent monolayer of Vero cells (CCL-81, ATCC) in 100 mm cell culture plates (Corning) at a 0.015 multiplicity of infection in OptiMEM (GIBCO). After 1-h incubation at 37 °C/5% CO2, OptiMEM containing 2% fetal bovine serum (FBS, GIBCO) was added

to the inoculated cells. Cells were further incubated at 37 °C/5% CO2 until 90–100% of cells exhibited cytopathic effect. To harvest virus, infected cells were scraped from plates, and excess growth medium was removed following low speed centrifugation (300 × g). Cell pellets were resuspended in 2 ml of OptiMEM, freeze-thawed, and centrifuged. Resulting supernatant containing virus was titered using the assay described in Section 2.3, aliquoted, and stored at −80 °C. To expand stocks of Moraten and Edmonston-Zagreb viruses from Attenuvax® and

M-VAC™ vaccines (respectively), lyophilized vaccines were reconstituted, serially diluted into serum-free DMEM (GIBCO), and added to Vero (Moraten) or MRC-5 (Edmonston-Zagreb) cells (CCL-171, ATCC) and then processed as described for MVeGFP. Vero cells were seeded at 2 × 104 cells/well in DMEM containing 5% FBS on 96-well ViewPlates CX-5461 in vivo (Perkin Elmer). Following a 1 h room temperature incubation [28], cell plates were incubated overnight at 37 °C/5% CO2. Virus was diluted 1:9 into formulation and thermally challenged.

After further diluting 1:3 into OptiMEM, samples were added to cells (25 μL) and centrifuged at low speed (311 × g) Tolmetin for 10 min. Assay plates were incubated at 37 °C/5% CO2 for 80 min to allow viral adsorption to cells. Fusion inhibitory protein (FIP, Z-d-Phe-Phe-Gly-OH, Bachem), dissolved in DMSO and diluted to a final concentration of 155 μM in OptiMEM containing 2% FBS/1% penicillin–streptomycin (GIBCO), was then added to wells (75 μL) to prevent syncytia formation and secondary infection. After 30 h at 37 °C/5% CO2, cells were fixed with 4% paraformaldehyde (EMS). Images were captured with a Cellomics VTi Arrayscan using a FITC filter and 2.5× objective lens ( Fig. 1). Infectious units (‘IU’) denote the titer of virus determined from the fluorescence-based assay as opposed to plaque-forming unit (pfu) titer measured by plaque assay. The complete HT formulation procedure will be described elsewhere (Development of an integrated high throughput system for identifying formulations of live virus vaccines with greater thermostability: application to the monovalent measles vaccine; manuscript in preparation). In brief, in-house Design of Experiment software created screening protocols. After 1.